Fish Odor Syndrome Treatment Market

Market Overview

Fish odor syndrome which is also referred as a stale fish syndrome or trimethylaminuria is a type of rare disease. Fish odor syndrome is a metabolic disorder which occurs due to failure of metabolic processes to alter the chemical trimethylamine. Mutation of the FMO3 gene is the key reason behind the occurrence of fish odor syndrome.

This disorder is diagnosed through urine testing and genetic testing of the FMO3 gene. Although, there no proper treatment available for fish odor syndrome but there are some ways to reduce its symptoms. Low doses of antibiotics along with laxatives are prescribed initially for fish odor syndrome treatment.

Also, nutritional supplement such as activated charcoal and chlorophyllin are prescribed to decrease the concentration of fish odor syndrome in urine. For a few patients, vitamin B12 supplements are also prescribed to enhance the FMO3 gene activity. Along with this medicinal treatment, some behavioral therapy will be prescribed to reduce depression and psychological symptoms.

Rising patent pool suffering from trimethylaminuria is the key factor propelling the revenue growth of fish odor syndrome treatment market over the forecast period. Also, an increasing initiative by National Organization for Rare Disorders to raise awareness regarding the fish odor syndrome treatment will propel the growth of the market.

Moreover, the rising focus of leading pharmaceutical companies to launch more innovative drugs for the treatment of fish odor syndrome has created the revenue growth opportunity in the near future. On other hand, limited availability of clinical data and less awareness regarding rare diseases in low-income countries may hamper the growth of fish odor syndrome treatment market.

Market Segmentation

Attribute	Details
Based on drug type	Antibiotics Vitamin B12 Supplements Others
Based on route of administration	Oral Injectable
Based on distribution channel	Hospital Pharmacies Retail Pharmacies Drug Stores Online Pharmacies

Key Players

Some of the key players across the value chain of fish odor syndrome treatment market are Pfizer Inc., Novartis AG, Johnson and Johnson, Sanofi SA, Merck Co & Inc., F. Hoffmann-La Roche AG, AbbVie Inc., GlaxoSmithKline plc., Eli Lilly and Company, Takeda Pharmaceuticals, Teva Pharmaceuticals and others.

The Report on Fish Odor Syndrome Treatment Market covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2014 - 2018
• Market Size & Forecast 2019 to 2029
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Market Drivers and Restraints

Regional analysis for Fish Odor Syndrome Treatment Market includes:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

 Report on Fish Odor Syndrome Treatment Market Highlights:

• Shifting industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size
• Recent industry trends
• Key competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

To know more about delivery timeline for this report Contact Sales